
GRTXD
Healthcare · Biotechnology · $19.7M market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 14, 2023 | Before the open | -79.44 | -66.00 | +16.9% |
| Aug 14, 2023 | Before the open | -75.66 | -96.00 | -26.9% |
| May 11, 2023 | Before the open | -85.95 | -100.00 | -16.3% |
| Nov 9, 2022 | Before the open | -100.60 | -120.00 | -19.3% |
| Aug 9, 2022 | Before the open | -101.95 | -108.75 | -6.7% |
| Mar 10, 2022 | Before the open | -152.02 | -128.00 | +15.8% |
| Nov 10, 2021 | Before the open | -153.55 | -172.00 | -12.0% |
| Aug 10, 2021 | Before the open | -165.76 | -176.00 | -6.2% |
| May 11, 2021 | Before the open | -166.17 | -150.00 | +9.7% |
| Nov 10, 2020 | Before the open | -154.15 | -138.00 | +10.5% |
| Aug 10, 2020 | Before the open | -150.48 | -150.00 | +0.3% |
| May 12, 2020 | Before the open | -139.23 | -148.00 | -6.3% |
| Dec 10, 2019 | Before the open |
Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development of a portfolio of small molecule dismutase (SOD) mimetics to improve radiotherapy in cancer. The company's lead product is tilarginine that is in Phase 1/2 trial of a pan-inhibitor of nitric oxide synthase to treat patients with highly resistant forms of breast cancer, including metaplastic breast cancer (MpBC) and other refractory…
| -94.00 |
| -102.86 |
| -9.4% |